Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025

Core Insights - Capricor Therapeutics is participating in one-on-one investor meetings and providing a corporate update at Leerink's Global Healthcare Conference 2025 from March 10-12, 2025 [1][2] - The company will present updates on its lead program, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD) [2][5] - Capricor is focused on developing cell and exosome-based therapeutics for rare diseases, with deramiocel being a key product candidate in late-stage development [3] Company Overview - Capricor Therapeutics, Inc. is a biotechnology company listed on NASDAQ (CAPR) that aims to redefine treatment for rare diseases through innovative therapies [3] - The lead product candidate, deramiocel, is an allogeneic cardiac-derived cell therapy showing immunomodulatory, antifibrotic, and regenerative actions [3] - The company is also developing exosome technology using its proprietary StealthX™ platform for various therapeutic applications [3] Strategic Partnerships - Capricor has entered into an exclusive commercialization and distribution agreement for deramiocel in the United States and Japan with Nippon Shinyaku Co., Ltd., pending regulatory approval [5]